{"disease":{"id":"unstable-angina-pectoris-during-ptca","name":"Unstable Angina Pectoris during PTCA","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"bivalirudin","indication_name":"Unstable Angina Pectoris during PTCA","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Angiomax","generic_name":"BIVALIRUDIN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"thrombin","drug_class":"Anti-coagulant [EPC]","quality_score":10,"revenue":null,"mechanism":"Bivalirudin directly inhibits thrombin by binding to its catalytic site and anion-binding exosite, preventing thrombus formation."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}